Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 26.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (3.846%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 26.50
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Renalytix PLC - Replacement

15 Mar 2024 10:23

RNS Number : 0590H
Polar Capital Holdings PLC
15 March 2024

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

Amendment - this form replaces RNS number 7712G, published at 18:14 on 13/03/2024. Changes have been made to Sections 1,2(a), 2(b) and 3(d). Amendments are marked with an asterisk (*). The full amended text is shown below.

1. KEY INFORMATION

(a) Full name of discloser:

Polar Capital LLP, the Investment Manager, disclosing on behalf of:

Polar Capital Funds PLC - Biotechnology Fund

Polar Capital Funds PLC - Healthcare Discovery Fund

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

RENALYTIX PLC

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

12/03/2024*

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

0.025 GBp Ordinary Shares

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

4,115,671*

4.11*

(2) Cash-settled derivatives:

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

4,115,671*

4.11*

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors' and other employee options)

Class of relevant security in relation to which subscription right exists:

0.025 GBp Ordinary Shares*

Details, including nature of the rights concerned and relevant percentages:

Agreed to subscribe to 9,750,390 new shares at a price of 0.2 GBP in Renalytix plc placing on 12 March 2024.*

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)*

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

15.03.2024

Contact name:

Ellie Martin

Telephone number*:

+44 20 3862 2578

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RETZZGMFGKMGDZM
Date   Source Headline
1st Dec 20227:00 amRNSClinical utility study data: further highlights
30th Nov 20227:00 amRNSResults for First Quarter of Fiscal Year 2023
29th Nov 20227:00 amRNSPublication of new real world evidence
22nd Nov 20227:00 amRNSNotice of Q1 FY23 Results
10th Nov 20227:00 amRNSPublication of Annual Report 2022 & Notice of AGM
9th Nov 20224:35 pmRNSPrice Monitoring Extension
3rd Nov 20227:00 amRNSRENX to Present at Stifel Healthcare Conference
31st Oct 20224:41 pmRNSSecond Price Monitoring Extn
31st Oct 20224:36 pmRNSPrice Monitoring Extension
31st Oct 20227:00 amRNSRenalytix Reports Full Year Fiscal 2022 Results
26th Oct 20229:05 amRNSSecond Price Monitoring Extn
26th Oct 20229:00 amRNSPrice Monitoring Extension
25th Oct 20227:00 amRNSKidneyIntelX Medicare Update
24th Oct 20227:00 amRNSNotice of Results
17th Oct 20227:00 amRNSPresentations accepte at ASN Kiney Week
17th Oct 20227:00 amRNSPresentations accepted at ASN Kidney Week
20th Sep 20227:50 amRNSDirectorate Change
12th Sep 20227:00 amRNSIssue of shares
8th Sep 20227:00 amRNSRenalytix to Present at H.C. Wainwright Conference
17th Aug 202212:00 pmRNSBusiness update
8th Aug 20227:00 amRNSPublication of clinical utility study in The AJMC
30th Jun 20227:00 amRNSRenalytix Reports Financial Results for Q3 of FY22
23rd Jun 20227:00 amRNSRenalytix to Report Financial Results for Q3
10th Jun 20227:00 amRNSMount Sinai clinical utility data
8th Jun 20227:00 amRNSRenalytix to Present at Growth Stock Conference
6th Jun 20227:00 amRNSData Presentations at ADA 82nd Scientific Sessions
6th Jun 20227:00 amRNSKidneyIntelX data shows ability to assess risk
29th Apr 20224:46 pmRNSTotal Voting Rights
22nd Apr 20227:00 amRNSGrant of Share Options
8th Apr 20227:00 amRNSSuccessful completion of $30.0m financing package
8th Apr 20227:00 amRNSIssue of shares
31st Mar 20227:05 amRNS$30.0 million financing package
31st Mar 20227:00 amRNSHalf-year Report
30th Mar 20227:00 amRNSTimothy Scannell appointed to the Board
29th Mar 20227:00 amRNSEnrollment Milestone for KidneyIntelX
25th Mar 20227:00 amRNSNotice of Results
9th Mar 20227:00 amRNSRenalytix Launches myIntelX
24th Feb 20227:00 amRNSPresentation of new clinical data for KidneyIntelX
22nd Feb 20227:01 amRNSRENX to Present at Cowen 42nd Annual Conference
22nd Feb 20227:00 amRNSTimothy Scannell to be appointed to board
27th Jan 20223:19 pmRNSGrant of Share Options
27th Jan 20227:00 amRNSConference attendance
11th Jan 20221:06 pmRNSPositive Study Results Published for KidneyIntelX
10th Jan 20227:00 amRNSPartnership with Singing River for KidneyIntelX
7th Jan 20227:00 amRNSAppointment of Jean M. Casner as CHRO
5th Jan 20227:00 amRNSRENX to present at 40th JP Morgan Healthcare Conf.
4th Jan 20227:00 amRNSJoint program with American Diabetes Association
17th Dec 20213:38 pmRNSResult of AGM
17th Dec 202111:26 amRNSDirector/PDMR Shareholding
13th Dec 20217:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.